Assessment cycle 2023 Q1 — page 5
Documents ratified in the 2023 Q1 assessment cycle, which ran from 1 January 2023 to 31 March 2023 and was ratified on 18 March 2023.
Documents ratified
-
Phase 1 ascending dose, phase 1 study of Retatrutide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low04 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Orforglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low14 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Orforglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low19 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of CagriSema (cagrilintide with semaglutide) in type 2 diabetes and obesity over as stated in the parent…
Very low05 Feb 2024 -
Phase 1 ascending dose, phase 1 study of Cagrilintide in obesity over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low31 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Mazdutide in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low10 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 2b study of Danuglipron in obesity over as stated in the parent protocol. The Institute holds no reported primary…
Very low03 Jul 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of Danuglipron in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported…
Very low06 Oct 2023 -
Single-arm open-label, phase 3 study of Liraglutide in type 2 diabetes over open-label extension of the parent trial. The Institute holds no reported primary result for…
Very low12 Mar 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Liraglutide in mash over as stated in the parent protocol. The Institute holds no reported primary result…
Very low14 Apr 2024 -
Phase 1 ascending dose, phase 1 study of Exenatide in type 2 diabetes over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low11 Oct 2023 -
Phase 1 ascending dose, phase 1 study of Exenatide in cardiovascular over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low07 Oct 2023 -
Randomised crossover, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low14 Dec 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in lipodystrophy over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low29 Aug 2023 -
Phase 1 ascending dose, phase 1 study of Tesamorelin in mash over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low13 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 1 study of Ipamorelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary…
Very low30 Jul 2023 -
Observational, phase 2 study of Ipamorelin in gastric emptying over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low11 Apr 2024 -
Randomised, double-blind, placebo-controlled, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low11 Sep 2023 -
Phase 1 ascending dose, phase 1 study of CJC-1295 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low16 Sep 2023 -
Randomised crossover, phase 1 study of Hexarelin in gh axis over as stated in the parent protocol. The Institute holds no reported primary result for this record and…
Very low12 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Hexarelin in lean-mass preservation over as stated in the parent protocol. The Institute holds no reported…
Very low13 Nov 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of GHRP-2 in gh axis over as stated in the parent protocol. The Institute holds no reported primary result…
Very low23 Nov 2023 -
Single-arm open-label, phase 1 study of GHRP-6 in gh axis over open-label extension of the parent trial. The Institute holds no reported primary result for this record…
Very low18 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 2b study of AOD-9604 in obesity over as stated in the parent protocol. The Institute holds no reported primary result…
Very low23 Sep 2023 -
Phase 1 ascending dose, phase 1 study of AOD-9604 in knee osteoarthritis over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low18 Jan 2024 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low19 Nov 2023 -
Single-arm open-label, phase 2 study of Thymosin beta-4 in wound healing over open-label extension of the parent trial. The Institute holds no reported primary result…
Very low12 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin beta-4 in wound healing over as stated in the parent protocol. The Institute holds no reported…
Very low05 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin beta-4 in cardiovascular over as stated in the parent protocol. The Institute holds no reported…
Very low29 May 2023 -
Randomised, double-blind, placebo-controlled, phase 1/2 study of LL-37 in wound healing over as stated in the parent protocol. The Institute holds no reported primary…
Very low17 Jun 2023 -
Phase 1 ascending dose, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low08 Jan 2024 -
Phase 1 ascending dose, phase 1 study of GHK-Cu in wound healing over as stated in the parent protocol. The Institute holds no reported primary result for this record…
Very low26 Feb 2024 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low29 Sep 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low23 May 2023 -
Observational, phase 3 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low13 Jun 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Thymosin alpha-1 in immune modulation over as stated in the parent protocol. The Institute holds no…
Very low03 Oct 2023 -
Randomised, double-blind, placebo-controlled, phase 2 study of Glutathione in cognition over as stated in the parent protocol. The Institute holds no reported primary…
Very low22 Jan 2024 -
Phase 1 ascending dose, phase 1 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for…
Very low21 Apr 2023 -
Randomised, double-blind, placebo-controlled, phase 3 study of Larazotide acetate in mucosal barrier over as stated in the parent protocol. The Institute holds no…
Very low01 Oct 2023 -
Randomised crossover, phase 1 study of Teduglutide in mucosal barrier over as stated in the parent protocol. The Institute holds no reported primary result for this…
Very low05 Jul 2023
page 5 of 13